A study by Vivancos et al. showed that two liquid biopsy platforms, OncoBEAMTM RAS CRC and IdyllaTM ctKRAS Mutation Test, had different sensitivity for identifying KRAS mutations in plasma samples from mCRC patients. Here, KRAS is linked to colorectal carcinoma.